Two Indian generic drugmakers, Hetero and Dr Reddy’s, will receive funding from the Gates Foundation and Unitaid, respectively, to manufacture and sell the biannual anti-HIV shot at approximately R692 per person annually. This development emphasizes the potential budget implications of lenacapavir, which is seen as a transformative solution in the fight against HIV.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
